Detalhe da pesquisa
1.
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
Eur Heart J
; 44(22): 2029-2042, 2023 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36939851
2.
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.
Oncologist
; 24(5): e196-e197, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30910868
3.
Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Breast Cancer Res Treat
; 175(1): 239-246, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30721443
4.
Development and Validation of a Clinical Score for Cardiovascular Risk Stratification of Long-Term Childhood Cancer Survivors.
Oncologist
; 23(8): 965-973, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29593100
5.
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.
Oncologist
; 23(8): 874-878, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29802220
6.
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Oncologist
; 22(6): 642-647, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28341761
7.
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Breast Cancer Res Treat
; 166(1): 241-247, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28710537
8.
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Oncologist
; 21(4): 418-24, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26984450
9.
Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer.
J Urol
; 195(1): 33-40, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26341576
10.
Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
Oncologist
; 20(10): 1105-10, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26240135
11.
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
Breast Cancer Res Treat
; 149(2): 489-95, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25552363
12.
Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival.
Breast Cancer Res Treat
; 146(2): 411-9, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24951268
13.
Cardiomyopathy associated with cancer therapy.
J Card Fail
; 20(11): 841-52, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25151211
14.
Cardiac metastases from head and neck cancer mimicking a myocardial infarction.
J Oral Maxillofac Surg
; 72(8): 1627-35, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24813774
15.
Incremental Utility of First-Pass Perfusion CMR for Prognostic Risk Stratification of Cancer-Associated Cardiac Masses.
JACC Cardiovasc Imaging
; 17(2): 128-145, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37410010
16.
17.
Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy.
Cardiooncology
; 9(1): 13, 2023 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895062
18.
Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
JAMA Cardiol
; 8(7): 697-702, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256614
19.
Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
J Am Heart Assoc
; 12(19): e029465, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37750581
20.
Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies.
J Exp Med
; 220(3)2023 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36534085